ID   LNCaP-Rf
AC   CVCL_4792
SY   LNCaP-RF
DR   cancercelllines; CVCL_4792
DR   Wikidata; Q54902853
RX   PubMed=11861374;
WW   https://web.archive.org/web/20160322000315/http://capcelllines.ca/details.asp?id=175
CC   Population: Caucasian.
CC   Doubling time: 34.14 hours (GrayJW panel).
CC   Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line).
CC   Derived from site: Metastatic; Left supraclavicular lymph node; UBERON=UBERON_8480056.
DI   NCIt; C4863; Prostate carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0395 ! LNCaP
SX   Male
AG   50Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 19
//
RX   PubMed=11861374;
RA   Zegarra-Moro O.L., Schmidt L.J., Huang H.-J., Tindall D.J.;
RT   "Disruption of androgen receptor function inhibits proliferation of
RT   androgen-refractory prostate cancer cells.";
RL   Cancer Res. 62:1008-1013(2002).
//